Related references
Note: Only part of the references are listed.The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase
D. R. Scott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
Gastric Acid-Dependent Diseases: A Twentieth-Century Revolution
George Sachs et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
Cell lineage distribution atlas of the human stomach reveals heterogeneous gland populations in the gastric antrum
Eunyoung Choi et al.
GUT (2014)
New and Future Drug Development for Gastroesophageal Reflux Disease
Carla Maradey-Romero et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2014)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
Yasuyoshi Arikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
High-Throughput Screening of Potassium-Competitive Acid Blockers
Mitsuyo Kondo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
Jun Matsukawa et al.
BIOCHEMICAL PHARMACOLOGY (2011)
A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)
Jai Moo Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: A wireless pH metry analysis
Rupa Banerjee et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Control of 24-hour Intragastric Acidity With Morning Dosing of Immediate-release and Delayed-release Proton Pump Inhibitors in Patients With GERD
Colin W. Howden et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shaojun Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Molecular mechanisms in therapy of acid-related diseases
J. M. Shin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Dyspepsia: Managing dyspesia in adults in primary care
David C. Metz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases
K Andersson et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Developments in the inhibition of gastric acid secretion
J Mössner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2005)
CYPC19 polymorphism and proton pump inhibitors
U Klotz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2004)
Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors
JM Shin et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Immunofluorescence detection of gastric H+/K+-ATPase and its alterations as related to acid secretion
XY Jiang et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2002)